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Abstract  Objectives: The aim of the study was to determine whether serum levels of lysylpyridinoline (LP) differ 
between diabetic foot osteomyelitis (DFO) and diabetic foot ulcers without osteomyelitis (cellulitis). Methods: A case 
controlled study was designed comparing the aforementioned groups. Subjects were classified as osteomyelitis and controls 
based on the International Working Group diagnostic criteria. Serum LP samples were analysed using enzyme linked 
immunosorbent assay. Results: The serum LP levels were significantly higher in the DFO group (n: 16) than the control 
group (n: 11): LP median ± SD of 9.3 ± 3.5 nmol/l, interquartile range (IQR) 6.8-11.2 in DFO compared to 2.1 nmol/l ± 3.5, 
IQR 0.7-4.2 in the controls, p=0.001. The receiver operator characteristic curve in the DFO was 0.9. The diagnostic 
sensitivity, specificity, positive and negative predictive values were 100%, 77.8%, 89.0% and 100% respectively. 
Conclusions: This appears to be the first evidence of serum LP elevation in diabetic foot osteomyelitis with potential 
diagnostic value in clinical setting.  
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1. Introduction 
Diabetic foot osteomyelitis (DFO) is a common 
complication of foot ulcers, with one review indicating rates 
between 20% and 68% [1]. DFO occurs in 2-3% of all 
diabetic patients and its chronicity contributes to a poor 
quality of life associated with pain, suffering and disability 
[2]. Mortality rates in individuals with DFO have been found 
to be almost twice as high compared to subjects without 
diabetes [3]. Diabetic foot bone infection (osteomyelitis) is a 
leading cause of hospitalisation and lower limb amputation 
worldwide costing >$40,000 per event [1, 4]. Thus early 
diagnosis of osteomyelitis may curtail hospitalisation for 
diabetic foot ulcer, lower limb amputation and death. 
The current diagnostic modalities for DFO have 
significant drawbacks due in part to non-availability in 
rural/remote and underserved healthcare centres. Plain 
radiography being cheap and readily available has a 
diagnostic sensitivity of only 54% and a specificity of 68%. 
Thus, it has poor diagnostic utility, especially at ruling out a 
diagnosis of osteomyelitis [5]. A Technetium 99m Bone 
Scan has a higher sensitivity of 81% and dismal specificity of  
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28%; thus are clinically useful to exclude DFO; however, 
less so for a positive diagnosis [6]. An indium-111 leukocyte 
scan has a sensitivity of 74% and a specificity of 68%; thus 
has equivalent specificity as plain radiography, with 
increased sensitivity yet available only in highly specialised 
centres [6, 7]. Magnetic resonance imaging (MRI) on the 
other hand has the highest sensitivity and specificity of the 
diagnostic imaging modalities with 90% and 79% 
respectively, and thus it is considered the gold-standard of 
the non-invasive diagnostic modalities [6, 8]. However, 
invasive procedure such as bone biopsy with histology and 
microbiological culture are considered the absolute gold 
standard techniques in diagnosing DFO yet the former is 
rarely performed in routine clinical practice [9]. Overall, the 
current diagnostic methods for osteomyelitis each have 
significant concerns including invasiveness (biopsy), 
extended lag-time to positivity (radiograph), poor sensitivity 
(plain radiograph) and poor specificity (bone scan). 
Leukocyte scans, bone scans, MRIs and biopsies all require 
specialised skills, are costly and have limited availability in 
resource poor regions [5]. Thus, at present there is no low 
cost option that has high diagnostic sensitivity and 
specificity that is available regardless of the level of the 
health service.   
The potential value of using lysylpyridinoline (LP) is of 
particular interest, as this method has not been previously 
used particularly in resource deprived communities where 
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modern diagnostic facilities are scarce and when available 
often beyond the reach of an average patient. The diabetic 
foot ulcer serves as a portal of entry for contiguous spread of 
microorganisms to the bone [4]. As osteomyelitis being a 
state of both enhanced bone resorption and bone formation it 
is proposed that bone turnover markers may be increased in 
blood circulation [10]. During both bone formation and 
resorption bone turnover markers are released, and thus it has 
been theorised that such markers could be of use in the 
diagnosis or exclusion of diabetic foot osteomyelitis. In spite 
of this no study on LP, a bone resorption marker, in diagnosis 
of diabetic foot ulcer despite of its demonstrable value in 
non-diabetic bone infections [11, 12]. We hypothesised that 
the DFO group will have significantly higher levels of LP 
compared to the controls. The aim of the study was to 
determine serum levels of LP in subjects with diabetic foot 
osteomyelitis and compare with diabetic foot ulcer without 
bone infection. 
2. Research Design and Methods 
The study was approved by the local hospital’s ethics 
committee and informed consent was obtained from the 
participants. Patients with diabetic foot ulcer aged greater 
than 18 years were included in the study. Subjects were 
excluded if they have Charcot’s joint or a known metabolic 
bone or joint diseases including rheumatoid arthritis or gout, 
osteoporosis or Paget’s disease or renal/hepatic failure. 
Other exclusion criteria included primary bone cancer or 
bone metastases. Subjects receiving thiazolidinedione, local 
or systemic immunosuppressive agents or known 
osteomyelitis unrelated to a diabetic foot ulcer were also 
excluded from the study. Foot wound or ulcer was defined as 
a full thickness lesion involving any portion of the foot or 
ankle [13, 14]. Wounds characterized as blisters, minor 
lacerations, or abrasions were excluded from the study. 
Wound infection was defined clinically, by criteria 
consistent with the International Working Group on the 
Diabetic Foot guidelines [9], i.e., the presence of wound 
purulence or at least two signs or symptoms of local 
inflammation or systemic symptoms of infection with no 
other apparent cause. All wounds were evaluated to 
determine the extent of soft tissue involved (cellulitis) and 
for any evidence of bone infection (osteomyelitis) [15]. For 
this study, osteomyelitis cases were defined by the 
intraoperative histologic findings of osteomyelitis or 
presence of probe-able bone underlying an ulcer supported 
by radiological (plain X-ray, magnetic resonance imaging 
(MRI) or radionuclide scanning) evidence of osteomyelitis in 
line with standard guideline [8, 9]. Subjects were allocated to 
the case group if they had findings consistent with 
osteomyelitis and control group was defined as subjects that 
met inclusion criteria however did not meet the diagnostic 
criteria for osteomyelitis (i.e. having cellulitis alone).  
On entry, detailed history and clinical examination was 
conducted and a protocol was completed. These included age, 
sex, diabetes control, site and depth of ulcer, and presence of 
associated diabetic complications including ischemic heart 
disease, peripheral vascular disease, peripheral neuropathy 
(i.e. loss of sensation using Semmes-Weinstein 
monofilament) and autonomic neuropathy (i.e. postural 
dizziness, impotence, episodic watery diarrhea and abnormal 
sweating). Diabetic retinopathy was diagnosed by 
experienced ophthalmologists based on the retinal images 
using digital fundus camera after maximal dilatation of the 
pupils. Morning fasting venous blood samples were taken, 
which were centrifuged at 3000g for 5 minutes, followed by 
-80°C storage. Serum haemoglobin a1c was measured by ion 
exchange high performance liquid chromatography 
(Beckman Coulter, CA, USA). Serum LP concentration was 
determined with the My BioSource (San Diego, California, 
USA) enzyme linked immunosorbent assay kit. The LP kit 
has a sensitivity of 1.0 ng/ml, recovery average of 99%, 
intra-assay reproducibility of <15% and inter-assay 
reproducibility of <15%. Absorption spectroscopy at a wave 
length of 450nm, in correlation with a line of best fit from 
standard solutions was used to determine the concentration 
of LP. The assay was blinded to the investigators. 
Table 1.  Characteristics of the study population 
Parameter Diabetic Foot Osteomyelitis 
Diabetic Foot 
Cellulitis (Control) 
P 
 
Subjects 16 11  
Age (Mean +SD) 70.8 ±6.9 (62.2-79.3) 
66.4±7.2 
(61.2-71.5) 0.24 
Male 87.5% 63.6% 0.15 
Indigenous 
Identified 86.7% 72.7% 0.38 
HbA1c 8.6% 9.3% 0.92 
Diabetic Retinopathy 75.0% 60.0% 0.43 
Peripheral 
Neuropathy 100.0% 100% 1 
Coronary Artery 
Disease 26.7% 60.0% 0.10 
Past Non-Traumatic 
Amputation 53.3% 40.0% 0.07 
Peripheral Vascular 
Disease 50.0% 30.0% 0.34 
Hypertension 86.7% 100% 0.59 
Statistical analysis was performed using Statistical 
Package for the Social Sciences version 23. The 
Shapiro-Wilk test was used to determine the normality of the 
continuous variables. The Students t test was used to analyse 
parametric continuous variable, and the Mann-Whitney U 
test was used to determine the non-parametric continuous 
variable data. Categorical data was analysed using the 
Chi-squared test. The data of the patients were used to 
determine the most suitable discriminating concentration of 
LP. These were calculated according to standard methods 
[16]. A p value less than 0.05 was predetermined as the 
cut-off value for statistical significance.  
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3. Results  
There were a total of 27 participants, with 11 controls and 
16 DFO, thus an enrolment ratio of 1:1.5. The combined 
demographic and clinical characteristics are shown in Table 
1 with a mean age of 67 years, predominantly male, 50% had 
a previous non-traumatic amputation and the mean HbA1c 
was 8.2% (66 mmol/mol). The median serum LP was 9.3 ± 
3.5 nmol/l, interquartile range (IQR) 6.8-11.2 in the diabetic 
foot osteomyelitis group and 2.1 ± 3.5 nmol/l, IQR 0.7-4.2 in 
the diabetic foot ulcer without osteomyelitis group (p=0.001) 
as depicted in Figure 1. The sensitivity, specificity, positive 
predictive value and negative predictive value of LP for the 
diagnosis of diabetic foot osteomyelitis were 100%, 77.8%, 
89.0% and 100% respectively as shown in Table 2; receiver 
operating characteristic (ROC) curve revealed diagnostic 
value of 0.9 (Figure 2). 
 
Figure 1.  Serum lysylpyridinoline levels in control group and in subjects 
with diabetic foot osteomyelitis. Horizontal line representing median, 
whisker as range and ▪ as outlier 
 
Figure 2.  Receiver operator characteristic curve of serum 
lysylpyridinoline levels in diagnosis of diabetic foot osteomyelitis 
demonstrating high diagnostic value 
Table 2.  Diagnostic values of serum LP levels in differentiating 
osteomyelitis from cellulitis in subjects with diabetic foot ulcer. LP 
concentrations were presented as median and standard deviation (SD) 
Parameter Diagnostic Values 
LP in Osteomyelitis group 9.3 ± 3.5 nmol/l 
LP in Control group 2.1 ± 3.5 nmol/l 
+ Cut Off > 3.56 nmol/l 
- Cut Off < 3.56 nmol/l 
p value P = 0.001 
95% confidence interval 0.7-1 
Sensitivity 100% 
Specificity 77.8% 
Positive Predictive Value 89.0% 
Negative Predictive Value 100% 
Area under the curve 0.9 
4. Discussion 
We have demonstrated markedly elevated serum levels of 
LP in subjects with diabetic foot osteomyelitis with 
non-overlapping interquartile ranges; thus, there is a 
statistically and numerically significant difference between 
osteomyelitis and control groups. The results are in 
concordance with Shi et al’s investigation of LP in spinal 
tubercular osteomyelitis and Springer and colleagues’ 
investigation of LP in mandibular osteomyelitis, both of 
which showed increased urinary LP in osteomyelitis subjects 
compared to controls [11, 12]. Our report is novel in that 
previously it was unknown whether the small volume of 
bone generally affected in diabetic foot osteomyelitis would 
raise serum LP. Experimentally induced femoral 
osteomyelitis in rabbits as reported by Southwood et al could 
be translated into osteomyelitis of smaller areas of bone in 
humans with diabetic foot osteomyelitis [17]. The only 
previous study on bone turnover markers in diabetic foot 
osteomyelitis was that reported by Nyazee et al showing no 
significantly raised serum levels of bone formation markers 
n-terminal telopeptide and bone specific alkaline 
phosphatase [18]. Thus, the current study, to the authors’ 
best knowledge, represents the first known report of 
diagnostic value of LP in diabetic foot osteomyelitis.   
Using LP in the diagnosis of diabetic foot osteomyelitis 
has the potential to reduce the dependency on sophisticated 
diagnostic imaging. The high sensitivity and negative 
predictive value of LP could in effect stop any negative result 
from undergoing any of the sophisticated radiological 
investigations. Thus early diagnosis of osteomyelitis using 
LP may curtail the need for lower limb amputation, however, 
confirmatory tests such as biopsy are invasive, accurate 
diagnostic tests (e.g. MRI) are costly and not readily 
available in most centres outside major cities. Use of 
radiographs in detecting osteomyelitis is cheap but has low 
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sensitivity [19, 20]. On the other hand, radioisotope scans are 
more sensitive than x-rays but are expensive and can be time 
consuming [7, 21]. We have previously reported use of an 
inflammatory marker -erythrocyte sedimentation rate (ESR) 
in diagnosing diabetic foot osteomyelitis [22] but its 
elevation in other inflammatory and neoplastic conditions 
limits its widespread use. We believe the increased LP in 
patients with diabetic osteomyelitis could be due to acute 
release of the bone resorption turnover marker from infected 
bone as noted by Nair et al [10]. Our preliminary results 
showed high specificity and positive predictive values of LP 
thus indicating a strong ability to rule-in the diagnosis of 
diabetic foot osteomyelitis. Bone turnover marker testing 
may have further utility in the rural and remote areas as LP 
may provide a triaging test to determine whether a suspected 
DFO should be evacuated to a larger centre for advanced 
diagnostic imaging. Finally there is a significant cost 
differential between the Medicare Benefits Scheme fees for 
LP (17 USD) and advance diagnostic imaging with magnetic 
resonance imaging and nuclear bone scan costing 
prohibitively higher, 284 and 235 USD respectively [23].  
Our results faced potential limitations including small 
sample size though it fitted with the outlined objectives of a 
pilot study. Secondly although combinations of histologic 
and microbiologic findings are usually considered the gold 
standard for the diagnosis of osteomyelitis, these procedures 
may not be routinely performed. Therefore, clinical, 
laboratory and imaging findings are often used as surrogates 
for diagnosing osteomyelitis [8]. We used the 
recommendation of the international working group on the 
diabetic foot in defining diabetic foot osteomyelitis in this 
study; basically histologic results and/or combination of 
clinical and radiological findings consistent with diagnosis 
of osteomyelitis [9]. Furthermore, histological diagnosis was 
not conducted on patients with a foot wound  in whom there 
was no suspicion of bone involvement though proved safe 
[24, 25], we believe it would be unethical to do this 
procedure on patients with no suspicion of osteomyelitis. In 
spite of theses our results are consistent with others findings 
of diagnostic usefulness of bone turnover markers in bone 
infection [11, 12]. 
In summary, this study has provided first evidence of LP 
being elevated in diabetic foot osteomyelitis compared to 
diabetic foot ulcers not complicated by osteomyelitis. 
Furthermore, our preliminary results suggest possible use of 
LP in diagnosing diabetic foot osteomyelitis. Finally, with 
further research LP may provide a viable, low cost, widely 
available rapid diagnostic methodology for diabetic foot 
osteomyelitis even in resource-deprived rural health centres. 
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